Formulation development of Captopril 25 mg. tablets
DOI:
https://doi.org/10.35954/SM2005.27.1.2Keywords:
Captopril; Dissolution; Formulation; Technology.Abstract
The objective of this work is the development of a technologically viable formulation of Captopril 25 mg tablets whose release is comparable to that of the innovator (Capoten®), using in vitro dissolution profiles as tools. Two formulations (F1 and F2) containing this active ingredient were designed. In each case, the characteristics of the mixtures obtained were evaluated to determine their technological feasibility, and F1 and F2 were found to be suitable for compression. For both formulations, the physicochemical parameters of the tablets were within the specifications of the regulations in force. The dissolution profiles of F1 and F2 were compared with those of the innovator in three media of different pH, applying model-dependent and model-independent methods. The in vitro dissolution profiles of F2 are similar to those of the innovator in the media studied, therefore F2 has a comparable in vitro release to Capoten®.
Downloads
Metrics
References
(1) FLOREZ J. “Farmacología Humana”, 3ª ed., cap. 21, págs. 344 a 353. Masson multimedia.
(2) BANKER G, RHODES C. “Drugs and the Pharmaceutical Sciences” Vol. 7 “Modern Pharmaceutics” Marcel Dekker inc., New York.
(3) FDA, Center for Drug Evaluation and Research (CDER), Guidance for Industry: "Waiver of In Vivo Bioavailability an Bioequivalence Studies for Immediate- Release Oral Dosage Forms Based on a Biopharmaceutics Classification System", Agosto 2000.
(4) United States Pharmacopeia, USP 27, Inc. Rockville.
(5) LIEBERMAN H, LACHMAN L. “Pharmaceutical Dosage Forms” vol II, cap. 5, págs. 185-262; Ed. Marcel Dekker, inc. New York 1981.
(6) “Remington: The Science and Practice of Pharmacy”, vols. I y II, 19ª Ed. 1995, Mack Printing Company, Pennsylvania.
(7) KIBBE A, “Handbook of Pharmaceutical Excipients” 3rd Ed., American Pharmaceutical Association Washington, D.C., Pharmaceutical press, London 2000.
(8) CAMPO M, PERDOMO I, IRAIZOZ A, RODRÍGUEZ M. Rev. Cubana Farm 2001;35(3):165-70.
(9) FDA, Center for Drug Evaluation and Research (CDER), “Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms”, agosto 1997.
(10) GORDON A, MARIVAL B, Software “Biofarmacia Moderna”, TSRL Inc. 2003, Universidad de Michigan.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
